Experimental antibody targets Hard-to-Treat blood cancers in early trial
NCT ID NCT05263271
First seen Apr 09, 2026 · Last updated May 12, 2026 · Updated 3 times
Summary
This early-stage study tested a new drug, gentulizumab, in 58 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to standard therapy. The drug works by blocking a protein called CD47 on cancer cells, helping the immune system attack them. The main goals were to check safety and find the best dose, but the trial was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.